3-Deoxyglucosone

Research use only, not for human use.

3-Deoxyglucosone(3-Deoxy-D-glucosone) is synthesized by the intermediate pathway of the melad and polyol reactions.

3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.

3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300?ng/ml or 1000?ng/ml 3DG-treated group. But at alower concentration (80?ng/ml) has no effects.3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca2+ levels by Fluo-3/AM determination (2.5?μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay.3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions.Western Blot Analysis Cell Line:STC-1 cells Concentration:300?ng/ml Incubation Time:1 hour Result:Upregulated TAS1R2, TAS1R3, and TRPM5 expression.

3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose)?impairs glucose tolerance with increased AUC, but the plasma glucagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats.3-deoxyglucosone?(gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased.Animal Model:SD rats Dosage:5, 20 and 50 mg/kg Administration:oral administration; once daily; 2 weeks Result:Was capable of accumulating in?intestinal?tissue?and thereby decreased?secretion?of?GLP-1?and insulin. ?

——

Others

Other Targets

GPX | Glucagon Receptor

——

——

4084-27-9

162.14

C6H10O5

>98% (HPLC)

——

[C@H](CC(C=O)=O)([C@@H](CO)O)O

——

(-20℃)

With Ice Pack

≥ 2 years